Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized Study to Assess Use of Androgen Deprivation to Enrich PSMA Expression and Improve Sensitivity of Staging PSMA PET/CT: The EnrichPSMA Trial

NCT07025369 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07025369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07025369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized Study to Assess Use of Androgen Deprivation to Enrich PSMA Expression and Improve Sensitivity of Staging PSMA PET/CT: The EnrichPSMA Trial
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
August 25, 2025
Completion date
March 31, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, stage iic prostate cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iv prostate cancer ajcc v8